ArticlePharmaceutics2021
Amorphous Solid Dispersions (ASDs): The Influence of Material Properties, Manufacturing Processes and Analytical Technologies in Drug Product Development.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Baicalein solid dispersion prepared by solvent evaporation enhances oral bioavailability and alleviates ulcerative colitis.International journal of pharmaceutics: X · 2026Article
- Hidden Solid-State Transformation of Darunavir in Low-Temperature Hot-Melt-Extruded Granules: Implications for Pharmacy Compounding and Routine Quality Control.Pharmaceutics · 2026Article
- Sparingly PEGylated Adipate Copolymers via Enzymatic Synthesis as Nano-Carriers for Solid Dispersions.Biomacromolecules · 2026Article
- Design and preparation of novel domperidone loaded polymeric blend electrospun nanofibers for improved oral pharmacodynamic activity.Drug delivery and translational research · 2026Article
- Amorphous Solid Dispersion Hydrogel Platform for Transdermal Delivery of Cannabidiol with Therapeutic Potential for Dermatitis.Pharmaceutics · 2026Article
- Synergistic role of monoacyl phospholipids and precipitation inhibitor in ternary solid dispersions: a case study of Aripiprazole.Drug delivery and translational research · 2026Article
- A Novel FloatingGels (Basel, Switzerland) · 2026Article
- Amorphous solid dispersions as a strategy to enhance the bioavailability and stability of formulations containing plant active ingredients: An integrative review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides.Drug design, development and therapy · 2026Review
- Double Particle Surface Modification to Improve Key Properties ofCurrent drug delivery · 2026Article
- Dissolution Rate and Stability Improvement of Hydrochlorothiazide and Valsartan by Co-Amorphous Formulation.Advances in pharmacological and pharmaceutical sciences · 2026Article
- New Strategies to Improve Drug Solubility and Its Impact on Bioavailability: A Patent Review (2015-2024).AAPS PharmSciTech · 2025Review
- Developing Multi-Component Solid Formulation Strategies for PROTAC Dissolution Enhancement.Molecular pharmaceutics · 2025Article
- CharacterizingMolecular pharmaceutics · 2025Article
- A Comparative Study of Flash Nanoprecipitation and Sequential Nanoprecipitation: Impact of Formulation Parameters on Drug-Loaded Nanoparticle Formation.Molecular pharmaceutics · 2025Article
- Recent Techniques to Improve Amorphous Dispersion Performance with Quality Design, Physicochemical Monitoring, Molecular Simulation, and Machine Learning.Pharmaceutics · 2025Review
- Investigating the Potential of Poly(2-ethyl-2-oxazoline) and Its Polymer Blends for Enhancing Fenofibrate Amorphous Solid Dispersion Dissolution Profile.Pharmaceutics · 2025Article
- Continuous Processing Strategies for Amorphous Solid Dispersions of Itraconazole: Impact of Polymer Selection and Manufacturing Techniques.Pharmaceutics · 2025Article
- Crystallizing the Uncrystallizable: Insights from Extensive Screening of PROTACs.Journal of the American Chemical Society · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poorly water-soluble drugs pose a significant challenge to developability due to poor oral absorption leading to poor bioavailability. Several approaches exist that improve the oral absorption of such compounds by enhancing the aqueous solubility and/or dissolution rate of the drug. These include chemical modifications such as salts, co-crystals or prodrugs and physical modifications such as complexation, nanocrystals or conversion to amorphous form. Among these formulation strategies, the conversion to amorphous form has been successfully deployed across the pharmaceutical industry, accounting for approximately 30% of the marketed products that require solubility enhancement and making it the most frequently used technology from 2000 to 2020. This article discusses the underlying scientific theory and influence of the active compound, the material properties and manufacturing processes on the selection and design of amorphous solid dispersion (ASD) products as marketed products. Recent advances in the analytical tools to characterize ASDs stability and ability to be processed into suitable, patient-centric dosage forms are also described. The unmet need and regulatory path for the development of novel ASD polymers is finally discussed, including a description of the experimental data that can be used to establish if a new polymer offers sufficient differentiation from the established polymers to warrant advancement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.